Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mirati nets $53.5mm through public stock sale

Executive Summary

Oncology company Mirati Therapeutics Inc. netted $53.5mm through the public sale of 3.25mm common shares at $17.50. The financing is the first for the company (formerly known as Canada-based MethylGene) since it commenced trading on Nasdaq after removing itself from the Toronto Stock Exchange. MethylGene re-incorporated as a US company in May 2013 following a plan of arrangement with Mirati, which at the time was just a holding company, and took the Mirati name.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies